Status:
RECRUITING
Metabolism-Informed Care to Aid Alaska Native People to Quit Smoking (QUIT)
Lead Sponsor:
Southcentral Foundation
Collaborating Sponsors:
National Institute of General Medical Sciences (NIGMS)
Conditions:
Smoking Cessation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to refine and pilot an intervention using the Nicotine Metabolite Ratio (NMR) to inform the selection of pharmacologic treatment to increase smoking abstinence among Alask...
Eligibility Criteria
Inclusion
- (Patients)
- Alaska Native or American Indian person by self-report
- eligible for or already receiving services at Southcentral Foundation (SCF)
- age 18 years or older
- daily smoking in the past 30-days
- if other nicotine or tobacco products are used, cigarettes are main product used
- planning to schedule an appointment with the Quit Tobacco Program to seek smoking cessation treatment in the next 30 days
- willing to make a quit attempt within 30 days of enrollment in the Quit Tobacco Program
- willing to have a blood test to inform their treatment
- willing to try a pharmacologic treatment
- willing to provide a saliva sample
- has phone service
- has access to broadband internet on mobile phone at home, work, or other location
- has an Android or iPhone mobile phone compatible with the Smokerlyzer app
- (Staff)
- \- Staff participants of qualitative interviews to assess acceptability and feasibility of the intervention must be a health care professional at Southcentral Foundation (SCF), involved in the care of one of the participants of the study, that is their care team staff; including but not limited to: primary care providers, tobacco treatment specialists/health educators, pharmacists, nurse case managers, behavioral health consultants, certified medical assistants, and lab technicians.
Exclusion
- (Patients)
- Participated in the prior study phase
- participated in a cessation program during the past 3 months
- their provider has not approved varenicline in their referral to the Quit Tobacco Program
- has history of serious hypersensitivity or skin reactions to varenicline
- has bleeding disorder or is currently receiving cancer treatment
- questionable capacity or impaired decision-making capacity
Key Trial Info
Start Date :
November 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06556238
Start Date
November 17 2025
End Date
June 1 2026
Last Update
November 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Anchorage Native Primary Care Center
Anchorage, Alaska, United States, 99508